Reform-a-nation Campaign/Docuseries Focuses on Injustice & Wrongful Convictions Like Anand Jon Alexander and Others in California and Beyond

Pandemonium and Mayhem on the Streets with Jimmie Lee-The Jersey Outlaw at the center of the action. Its No Holds Barred, Uncanny and Unpredictable, with the best in comedy and is rated one of the best TV comedy shows now.

BHS, Inc., a leading provider of material handling equipment, recently promoted internal employee Ken Cooley to the role of Dealer Development Manager.

A facility expansion for BHS, Inc. offers more space for research and development of Industry 4.0 products and expanded inventory needs.

Kennedale Alliance of Business Owners (KABO) Formed to Advocate on their Behalf

U.S. Senate

Buckley

Ms. Marilyn Klinger of Los Angeles, California, is honored by the International Association of Who's Who as one of America's Most Influential Attorneys for her achievements within the field of Law.

Cynthia Garnholz, of St. Louis, Missouri, is recognized by the International Association of Who's Who as one of America's Most Influential Attorneys for her extensive achievements within the field of Law.

Melted Wax Studio to Open Soon in Suite 309 Inside the New Salon and Spa Galleria in Lake Worth

Reef fishing net transformed from "dangerous" to "desirable" ReefCycle sunglasses

Held at the AllBright Collective in West Hollywood, Guests at Chella Beauty's Exclusive Event Enjoyed Pampering, Mingling and a Chance to be the First to Experience Chella's New Palette.

The Connecticut law firm was honored in the personal injury and medical malpractice fields by the prestigious U.S. News - Best Lawyers 'Best Law Firms' publication.

The 2019 Tri-State Grain Growers Convention is soon to kick off in Spokane, Wash., Nov. 13-16 at the Davenport Grand Hotel.

Karl Truman Law Office focuses on high-quality client service in and around Louisville, Kentucky, and Jeffersonville, Indiana

TOP platform is an international campaigner that invites all freelancers no matter where they might be in the world to sign up and explore the opportunity to make money online by offering services through this digital marketing agency.

After helping entrepreneurs find success in business, Ashely is ready to share her knowledge with a larger audience.

Discussion Will Spotlight Why Women Should Take the Lead in Politics Awards Presentation Will Honor Local Notables

The leading business school news hub surveys over 750 business schools admits and prospects about getting an MBA in the current COVID-19 environment.

It’s no secret, a large number of high-profile companies have taken a serious beating since the pandemic’s onset. Possibly none more well-known than Disney (DIS). COVID-19 has necessitated theme park closures, a halt of live film production, and a delayed movie release schedule – all resulting in last week’s crushing F2Q20 report.Yet, Northland analyst Bernie McTernan argues that there are several reasons to remain positive on the House of Mouse.Glimmers of hope were provided during the earnings call, as Disney announced it will reopen its Shanghai theme park next week on May 11. McTernan assumes that domestically, Disney’s parks will open in September. Nevertheless, the forced enclosures are set to impact the balance sheet for a while, and McTernan forecasts it will take “at least two years for Disney to generate the revenue/segment operating income they could have in FY'20.”Disney has also taken emergency measures to preserve cash flow through the pandemic. The company has suspended the dividend, reduced capex and furloughed employees. Although drastic, in an environment which is likely resulting in negative FCF, McTernan believes the measures should “provide a margin of safety.”“Importantly,” McTernan added, “We believe these levers can be switched back on when the operating environment begins to normalize.”But there is another recent positive development for investors to consider. When Disney announced in April that the launch of its new streaming service Disney+ had exceeded expectations and already boasted 50 million global subscribers, the numbers took the Street by surprise. McTernan believes there’s more to come.“We estimate Disney+ will reach 65M global subscribers by the end of September '20E and attain profitability in FY'23E, a year earlier than originally guided… As cord cutting grows, Disney+ is the reason to own the stock,” McTernan opined.To this end, McTernan keeps a Buy rating on Disney, along with a $130 price target, which implies nearly 20% upside from current levels. (To watch McTernan’s track record, click here)And what abut the rest of the Street? Based on 11 Buy ratings, 10 Holds and 1 Sell, Disney has a Moderate Buy consensus rating. With an average price target of $120.35, the analysts expect upside of nearly 12% over the coming months. (See Disney stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * RBC: 2 Strong Value Stocks to Buy Now * Look Beyond 2Q, General Motors Will Outperform the Sector, Says Analyst * Investor James Richman Bets GE Stock Is Set to Experience Almost 100% Rally  * Coronavirus Vaccine Could Add Massive Value to This Small-Cap Stock, Says Analyst

When tickets for the May 11 reopening of Shanghai Disneyland went on sale, they sold out within minutes. Park officials said they are taking "a deliberate approach”, such as requiring physical distancing and sharply reducing capacity. Jen Rogers, Myles Udland and Akiko Fujita discuss what the reopening of the first major theme park says about consumer demand post-coronavirus.

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing. An analyst at BofA Securities said Friday that now is the time to go from defensive to offensive in the sector, as quarantines are winding down in several parts of the globe.The Biopharma Analyst Analyst Geoff Meacham shortlisted Eli Lilly And Co (NYSE: LLY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Bristol-Myers Squibb Co (NYSE: BMY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Amgen, Inc. (NASDAQ: AMGN) as biopharma stocks where he would put his money to work.The analyst has the following ratings and price targets for the shares: * Lilly: Buy/$165 * Vertex: Buy/$300 * Bristol-Myers Squibb: Buy/raised the price target from $75 to $80 * BioMarin: Buy/lifted price target from $110 to $120 * Amgen: Buy/price target increased from $265 to $2755 Reasons For BofA's Bullish Disposition BofA is increasingly bullish on the biopharma group due to the following factors, Meacham said: * Expectations for robust revenue growth of 6% in the second half of 2020 compared to the first-half, which is double that of the S&P 500's revenue growth. * Reasonable price-earnings for the stocks in the sector. * Many value-creating events lined up for the second half. * Lower policy risk stemming from goodwill earned from the COVID-19 pipeline. * A consistently positive FDA backdrop.Q1 Earnings Get 'A' Grade All of the big biotechs and major pharma companies reported both revenue and adjusted EPS beats in the first quarter, with Lilly and Vertex even raising some parts of their 2020 guidance, Meacham said.Citing slower new starts and forex headwinds, Bristol-Myers Squibb and BioMarin lowered their 2020 revenue guidance, but maintained their EPS guidance, the analyst said. Meacham expressed surprise at Merck & Co., Inc. (NYSE: MRK) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) lowering their 2020 revenue and adjusted EPS guidance, given his belief that oncology or orphan diseases wouldn't be as sensitive to COVID-19 disruption.See also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Lilly One of The Higher Quality Stocks In BofA's Coverage Lilly is a source of differentiated growth given its early product cycle and diversified base business, including diabetes, immunology and immunotoxicology and migraine, and an advancing late-stage pipeline of potentially best-in-class or first-in-class therapies, Meacham said.The analyst said he likes Lily's potential for additional earnings growth in 2020-2021 and views Lilly as one of the higher quality stocks in his coverage despite its higher valuation. The prospects for 2021 look attractive, with selpercatinib potentially launching in non-small cell lung cancer and thyroid cancer by year's end, and tirzepatide approval in 2021 representing a "step change" for the diabetes franchise, he said. Consensus For Vertex To Move Higher? Vertex has a richer -- though well-deserved -- valuation, due to its differentiated growth profile, Meacham said.Given that Vertex's commercial execution is largely unaffected by the COVID-19 pandemic, the analyst said investors will begin to look forward to 2021 sooner than for other companies with more commercial risk.BofA expects consensus estimates to continue to move higher, making Vertex's valuation even more attractive.Bristol-Myers Has Highly Differentiated Growth With an estimated 8% revenue growth and 19% EPS growth in 2021 compared to 5-6% and 12%, respectively, for peers, and with six new launches expected this year, 2020 is shaping up to be a very robust period for Bristol-Myers despite the ongoing COVID-19 headwinds, Meacham said. The analyst said the company's growth looks highly differentiated.An increasingly diversified product mix and beatable launch expectations position the company for meaningful upside to consolidated P&L, with improving synergies, he said. BioMarin's 'Game-Changing' Late-Stage Pipeline BioMarin's late-stage pipeline in valrox and vosoritide have improved its growth outlook, Meacham said.The analyst termed the company's late-stage pipeline as "game-changing." The second-half launch of Roctavian is the most important catalyst for the company this year, with the product likely to accelerate the company's already above-average growth profile, he said. "We see BioMarin as one of the higher quality names in our coverage universe given its clean growth story and it remains our SMid cap top pick." Amgen Looks To New Product Growth To Compensate For Legacy Product Erosion The long-term outlook for Amgen's Otezla is improving given the recently announced Phase 3 data for mild-to-moderate psoriasis, Meacham said.The company rapidly refocused its story from legacy product erosion to new product growth with the acquisition of Otezla from the Bristol/Celgene deal, the analyst said. "Since then Amgen's growth profile has only improved, led by an expanded addressable market for Otezla, outperforming Amgen Biosimilars and Evenity franchises, aggressive formulary negotiation for Aimovig, and an exciting pipeline in AMG 510 and tezepelumab looking to contribute as soon as 2021." The Price Action The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) was last seen trading up 1.25% to 128.76, adding to its 5.6% year-to-date gain. Related Link: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace See more from Benzinga * The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda * The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500 * The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

What happened to my stimulus money? Many who receive government benefits and others continue to wonder in early May.

Popular communications platform provider Zoom Video announced on Thursday that it has acquired secure messaging and file-sharing service Keybase for an undisclosed sum. The move is the latest by the company as it attempts to bolster the security of its offerings and build in end-to-end encryption that can scale to the company’s massive user base.

read more

Underpins company plan to expand commercialization and definitive manufacturing relationships

Billy Johnson of the Billy Johnson Law Firm in Pikeville, Ky., says highways are especially dangerous during summer months.

Billy Johnson, a personal injury attorney in Pikeville, KY, said that a greater awareness of the threats facing motorists could reduce the number of vehicle crashes.

Columbia attorney Mark Evans encourages drivers and lawmakers alike to improve Missouri's poor record on road safety.

Chip Evans said that the innovative design was focused on usability and improved client interaction.

To accommodate rapid growth and expansion of the product line, BMS promotes one of their top dealers to lead them into the next decade.

In celebration of National Motorcycle Safety Awareness Month, Personal Injury Attorney Ed Smith Offers Tips to Help Motorcyclists Ride Safely

Election Day has come and gone. Yesterday, our daily Transportation Headlines highlighted the Center For Transportation Excellence's state-by-state results of all transportation ballot measures in 2010.

43 of 56 measures passed: a 77% success rate.

Free Webinar: Trends And Results From 2010 Transportation Ballot Measures (Register Here)

Hosted by the Center for Transportation Excellence, NAPTA and APTA State Transit Association Leaders

Fri, Nov 5, 2010 10:00 AM - 11:00 PM PST

CFTE's State-By-State 2010 Transportation Ballot Measures results

CFTE's report: Transportation Finance At The Ballot Box: Voters Support Increased Investment & Choice (34p. PDF)

Transportation For America's Future Of Transportation Nation Survey (26p. PDF : March, 2010), for which a summary of survey findings can be found here.

JW Michaels makes comparing executive salaries of the financial service industry a snap with release of compensation data report data

Vice President Stephen Lapierre represents developer Verdad Real Estate in acquisition of properties for two Popeyes restaurants

Charney Investment Group is pleased to announce the addition of its newest team member, Sarah White.

In today’s connected and digital business world, more and more companies are relying on service providers to help achieve their business objectives. Because of this, SOC (System and Organization Control for Service Organizations) reports are gaining more importance. SOC reports… Read More

The post SOC Reports: What Are They and Why Do They Matter to My Business? appeared first on Anders CPAs.

With many organizations having machine learning models running in production, some are discovering that inefficiencies exists in the first step of the process: feature definition and extraction. Robust feature management is now being realized as a key missing part of the ML stack, and improving it by applying standard software development practices is gaining attention.

As usual, my dilemma for finding the perfect moisturizer has not yet solved. So, after using the hyaluronic acid serum (Marine Hyaluronics) from The Ordinary, this is my second hyaluronic acid serum and I was and was completely unsure of what to expect. The best part is I am writing the review almost a month […]

The post Dot & Key Water Drench Hydrating Hyaluronic Acid Serum Concentrate appeared first on Perfect Skin Care for you.

The eye cream concentrate is very creamy and perfect for the eye area, especially if you have dry skin. The product will last you quite long since you need only a drop for each eye. It smells really nice without being over-powering and it hydrates the under-eye area pretty well. I also observed that it was not too rich for my under eye area and I did not suffer from any milia seeds or breakouts.

The post Dot & Key Hydration Range appeared first on Perfect Skin Care for you.

Christina Bielaszka-DuVernay, editor of Harvard Management Update.

Featuring the ideas of Vineet Nayar, Jeff Stibel, and Stewart Friedman.

Robert Iger, CEO of Disney.

Robert Kaplan, Harvard Business School professor and author of "What to Ask the Person in the Mirror."

Tim Sullivan, editorial director of Harvard Business Review Press and coauthor of "The Org: The Underlying Logic of the Office."

John Mackey, co-CEO of Whole Foods Market and coauthor of "Conscious Capitalism: Liberating the Heroic Spirit of Business."

The tech luminaries on bundling and unbundling in the digital age.

Walter Frick, HBR editor, explains why we valorize tech heroes from the past, but scoff at today's entrepreneurs.